VIR Vir Biotechnology, Inc.
8-K Current Report
Filed: March 2, 2026
Health Care
Biological Products, (No Diagnostic Substances)Vir Biotechnology, Inc. (VIR) 8-K current report filed with SEC EDGAR on March 2, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
AI Filing Analysis8-K
Item 8.01 · Other Events
- • Offering closed Feb 27, 2026; 20,294,117 shares sold including full overallotment exercise at $8.50/share
- • Gross proceeds ~$172.5M before underwriting discounts and offering expenses
Other Vir Biotechnology, Inc. 8-K Filings
Get deeper insights on Vir Biotechnology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.